Angioimmunoblastic T-Cell Lymphoma Market
According to Intent Market Research, the Angioimmunoblastic T-Cell Lymphoma Market is expected to grow from USD 2.2 billion in 2023 at a CAGR of 10.9% to touch USD 4.6 billion by 2030. The Angioimmunoblastic T-Cell Lymphoma Market is dominated by key players such as Bristol Myers Squibb, Novartis International AG, Merck & Co., Inc., Roche Holding AG, AbbVie Inc., Amgen Inc., Eli Lilly and Company, Johnson & Johnson, Pfizer Inc., Takeda Pharmaceuticals, Celgene Corporation (now part of Bristol Myers Squibb), AstraZeneca PLC, Regeneron Pharmaceuticals.